Jessica Jensen
Chief Tech/Sci/R&D Officer chez POINT Biopharma, Inc. (United States)
Profil
Jessica Jensen is currently the Executive Vice President-Clinical Development at POINT Biopharma, Inc. in the United States.
Prior to this, she was the Senior Vice President-Clinical Development at Progenics Pharmaceuticals, Inc. from 2018 to 2020.
She will also be the Executive Vice President-Clinical Development at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Jensen has a graduate degree from George Washington University and an undergraduate degree from St. Joseph's University.
Postes actifs de Jessica Jensen
Sociétés | Poste | Début |
---|---|---|
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Anciens postes connus de Jessica Jensen
Sociétés | Poste | Fin |
---|---|---|
POIT BIOP | Chief Tech/Sci/R&D Officer | 27/12/2023 |
PROGENICS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/08/2020 |
Formation de Jessica Jensen
George Washington University | Graduate Degree |
St. Joseph's University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
POIT BIOP | Health Technology |
Entreprise privées | 2 |
---|---|
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |